Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
iDEL Therapeutics | Mar 2026Led | $10 MSeed | |
T-Curx | Dec 2025Led | $20 MSeries A | |
ImmunOs Therapeutics | Sep 2024Led | $11 MSeries C | |
Tubulis | Mar 2024Participated | $140 MSeries B | |
TOLREMO therapeutics | Sep 2023Led | $38 MSeries A | |
Tricares | Dec 2022Participated | $54 MSeries C | |
ImmunOs Therapeutics | Jun 2022Participated | $74 MSeries B | |
Tubulis | May 2022Participated | $63 MSeries B | |
Precirix | Mar 2022Participated | $88 MSeries B | |
Scenic Biotech | Mar 2022Led | $31 MSeries A | |
Cardior Pharmaceuticals | Aug 2021Participated | $75 MSeries B | |
Topas Therapeutics | Jul 2021Participated | $21 MSeries B | |
iDEL Therapeutics | Mar 2026Led | $10 MSeed | |
T-Curx | Dec 2025Led | $20 MSeries A | |
ImmunOs Therapeutics | Sep 2024Led | $11 MSeries C | |
Tubulis | Mar 2024Participated | $140 MSeries B | |
TOLREMO therapeutics | Sep 2023Led | $38 MSeries A | |
Tricares | Dec 2022Participated | $54 MSeries C | |
ImmunOs Therapeutics | Jun 2022Participated | $74 MSeries B | |
Tubulis | May 2022Participated | $63 MSeries B | |
Precirix | Mar 2022Participated | $88 MSeries B | |
Scenic Biotech | Mar 2022Led | $31 MSeries A | |
Cardior Pharmaceuticals | Aug 2021Participated | $75 MSeries B | |
Topas Therapeutics | Jul 2021Participated | $21 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 14 | 8 |
| Series B | 5 | 15 |
| Series C+ | 7 | 5 |
| Other Equity | 0 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '07 | 1 |
| May '07 | 0 |
| Jun '07 | 0 |
| Jul '07 | 0 |
| Aug '07 | 0 |
| Sep '07 | 0 |
| Oct '07 | 0 |
| Nov '07 | 0 |
| Dec '07 | 0 |
| Jan '08 | 0 |
| Feb '08 | 0 |
| Mar '08 | 0 |
| Apr '08 | 0 |
| May '08 | 0 |
| Jun '08 | 0 |
| Jul '08 | 0 |
| Aug '08 | 0 |
| Sep '08 | 0 |
| Oct '08 | 0 |
| Nov '08 | 0 |
| Dec '08 | 0 |
| Jan '09 | 0 |
| Feb '09 | 0 |
| Mar '09 | 0 |
| Apr '09 | 0 |
| May '09 | 0 |
| Jun '09 | 0 |
| Jul '09 | 0 |
| Aug '09 | 0 |
| Sep '09 | 0 |
| Oct '09 | 1 |
| Nov '09 | 0 |
| Dec '09 | 1 |
| Jan '10 | 0 |
| Feb '10 | 0 |
| Mar '10 | 0 |
| Apr '10 | 1 |
| May '10 | 0 |
| Jun '10 | 0 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 1 |
| Oct '10 | 1 |
| Nov '10 | 1 |
| Dec '10 | 1 |
| Jan '11 | 1 |
| Feb '11 | 1 |
| Mar '11 | 2 |
| Apr '11 | 0 |
| May '11 | 2 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 1 |
| Sep '11 | 0 |
| Oct '11 | 0 |
| Nov '11 | 0 |
| Dec '11 | 0 |
| Jan '12 | 0 |
| Feb '12 | 0 |
| Mar '12 | 0 |
| Apr '12 | 1 |
| May '12 | 1 |
| Jun '12 | 0 |
| Jul '12 | 0 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 1 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 1 |
| Nov '13 | 2 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 1 |
| Apr '14 | 1 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 1 |
| Oct '14 | 0 |
| Nov '14 | 1 |
| Dec '14 | 1 |
| Jan '15 | 2 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 1 |
| Oct '15 | 1 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 1 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 1 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 1 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 1 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 2 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 59 |
| Space & Frontier Tech | 10 |
| Manufacturing | 6 |
| Social & Community Platforms | 1 |
| Developer Tools | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 5 |
| $5M-$10M | 8 |
| $10M-$25M | 21 |
| $25M-$50M | 16 |
| $50M-$100M | 8 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 56 |
| United States | 3 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| EQT Life Sciences (LSP) | 14 |
| VI Partners | 11 |
| High-Tech Grunderfonds | 9 |
| Boehringer Ingelheim | 7 |
| Aeris Capital | 6 |
| Bayern Kapital | 6 |
| Vesalius Biocapital | 6 |
| Andera Partners | 5 |
| BB Biotech Ventures | 5 |
| Forbion | 5 |
| Gimv | 5 |
| HBM Partners | 5 |
| Initiative Capital Romandie | 5 |
| Schroder Adveq | 5 |
| Sofinnova Partners | 5 |
| Banexi Ventures Partners | 4 |
| coparion | 4 |
| NeoMed Management | 4 |
| OrbiMed | 4 |
| Seventure Partners | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 27 | 46% |
| Participating | 32 | 54% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 19% |
| Co-led | 22 | 81% |
Team
General Partner
Managing General Partner
Office Manager
Venture Partner
General Partner
Partner
Chief Financial Officer & Partner
General Partner
Venture Partner
